金斯瑞生物科技(01548.HK)：申辦研究的八篇摘要已入選2022年ASCO年會和2022年EHA線上線下混合會議
格隆匯5月18日丨金斯瑞生物科技(01548.HK)公吿，傳奇生物科技股份有限公司（為公司非全資附屬公司，其股份以美國存托股份形式於美國納斯達克全球精選市場上市）宣佈，公司申辦研究的八篇摘要已入選2022年美國臨牀腫瘤學會(ASCO)年會（2022年ASCO年會）和2022年歐洲血液學協會(EHA)線上線下混合會議（2022年EHA線上線下混合會議）。
這些報吿將提供CARTITUDE臨牀開發計劃的最新資料，該項目旨在評估西達基奧侖賽（CARVYKTI, cilta-cel）用於多發性骨髓瘤治療的安全有效性，西達基奧侖賽是一種靶向B細胞成熟抗原(BCMA)的嵌合抗原受體T細胞(CAR-T)療法。
CARTITUDE-1長期（末例患者入組後兩年）隨訪結果將在2022年ASCO年會和2022年EHA線上線下混合會議上以海報形式呈現。CARTITUDE-1是一項針對既往接受過多線治療的復發或難治性多發性骨髓瘤(R/R MM)患者的1b/2期研究，其結果支持了美國食品藥品監督管理局(FDA)對CARVYKTI的批准。
報吿還將呈現CARTITUDE-2研究隊列A和隊列B的更新資料。該項多隊列研究旨在評估西達基奧侖賽在多發性骨髓瘤的各種治療場景（包括前線治療）中的安全性和有效性。隊列A包括既往接受過1–3線治療後出現進展且對來那度胺耐藥的多發性骨髓瘤患者，其資料將在2022年ASCO年會和2022年EHA線上線下混合會議上以海報形式呈現。隊列B包括在初始治療（包括蛋白酶體抑制劑和免疫調節劑藥物）後出現早期復發的患者，其資料將在2022年ASCO年會上以海報展示，並在2022年EHA線上線下混合會議上以口頭報吿的形式呈現。其他資料也將在這兩次會議上公佈，包括來自真實世界研究LocoMMotion的資料，該研究是一項在常規臨牀實踐中針對R/R MM患者進行真實世界標準治療的前瞻性跨國研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
